Gilead-IOCB collaboration: Professor Antonín Holý addressing a press conference at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague. Representing Gilead Sciences are Michael Riordan, the founder and CEO of Gilead; John Martin, Gilead's Vice-President of R&D; and Gilead R&D officers Norbert Bischofberger, Mick Hitchcock and Bill Lee. Representing IOCB, in addition to Professor Holý, are Ivan Votruba (IOCB Senior Scientist) and Karel Martinek (Director of the IOCB). Professor Holý was the first to synthesize tenofovir (Viread), an essential component of Truvada and other widely-used anti-HIV and anti-HBV medicines developed by Gilead Sciences under a licensing and research collaboration agreement initiated in 1991. Holý's co-inventor of tenofovir was Professor Erik De Clercq of the Rega Institute at the University of Leuven, Brussels. Photo dated early 1990s.